Table 4.

Complications of HCT during the first 100 days and their attendant Day-200 Non-Relapse Mortality Hazard Ratios, 2013-2017.

Complications of allogeneic hematopoietic cell transplant during 2013-2017	Number of patients*	Hazard Ratio for Day-200 Non- Relapse Mortality (95% CI)
Peak total serum bilirubin ≥68.4 μmol/L (4 mg/dL)	123	11.94 (8.16 – 17.47)
Peak total serum bilirubin ≥171 μmol/L (10 mg/dL)	29	33.85 (20.06 – 57.11)
Serum creatinine 2-times baseline	254	6.63 (4.60 – 9.57)
Serum creatinine 3-times baseline	67	15.47 (9.97 – 24.01)
Renal Replacement Therapy	39	20.80 (13.03 – 33.22)
Mechanical ventilation	77	15.85 (10.72 – 23.44)
Jaundice + Renal Replacement Therapy + Mechanical ventilation	19	36.70 (19.31 – 69.77)
Any CMV infection†	501	1.23 (0.73 – 2.08)
CMV DNA >250 IU/mL†	288	2.33 (1.42 – 3.84)
CMV DNA >1000 IU/mL†	138	2.82 (1.68 – 4.75)
CMV disease b	24	2.00 (0.72 – 5.56)
Gram negative bacteremia	74	5.16 (3.22 – 8.24)
Invasive mold infection	42	9.73 (5.83 – 16.22)
GVHD grade 2-4	784	1.45 (0.95 – 2.22)
GVHD grade 3-4	135	5.29 (3.59 – 7.81)

^*See Table 3, Frequency of events among all patients transplanted during 2013-2017.

^†Among CMV-seropositive patients only.